Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 5/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937265 | 1.00 | P2RY6 (0.34) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL19981007 | 1.00 | P2RY6 (0.34) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL10459464 | 1.00 | P2RY6 (0.34) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL20215740 | 1.00 | P2RY6 (0.34) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL20459987 | 1.00 | P2RY6 (0.34) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL14946314 | 0.92 | MAPT (0.32) | P2RY6P2RY14NT5EMAPTROCK2 | |
| SCHEMBL16229229 | 0.89 | MAPT (0.31) | MAPTABL1RIN1 | |
| SCHEMBL13151571 | 0.89 | P2RY6 (0.47) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL6365808 | 0.89 | P2RY6 (0.47) | P2RY6P2RY14NT5EP2RY2P2RY4 | |
| SCHEMBL13672352 | 0.89 | P2RY6 (0.47) | P2RY6P2RY14NT5EP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079768-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | BONAC CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
| US-9481702-B2 | Glycoside compound, method for producing thioether, ether, method for producing ether, method for producing glycoside compound, method for producing nucleic acid | BONAC CORPORATION (JP) | 2016-11-01 | — | — | US | disclosed |
| US-20140206856-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | BONAC CORPORATION (JP) | 2014-07-24 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RY6 339/4885P2RY14 531/4885NT5E 10/4885 |
| US-20140206856-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | DDOST, TENT4A, TRDMT1 | P2RY6 760/4885P2RY14 1166/4885NT5E 523/4885 |
| US-20180079768-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | TST, DIMT1, DERA | P2RY6 2856/4885P2RY14 3285/4885NT5E 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.